Niusule Biotech signs distribution agreement to market Gummy Bear products in Shanghai

Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company's popular Gummy Bear products will be distributed in Shanghai, the largest city in China. The Company has entered into a one year distribution contract with Hainan Qi Zheng Pharmaceutical Co., Ltd. ("Hainan Qi Zheng"), a leading distributor in Shanghai and Zhejiang Province, China.

Hainan Qi Zheng will distribute Niusule's Gummy Bear products across Shanghai through drugstores, shopping malls, and children stores. Under the contract, Hainan Qi Zheng is responsible for distributing Niusule's Gummy Bear products in Shanghai to 100 retail outlets by December 10, 2009 and to 280 retail outlets by end of 2010. Niusule will advertise its products in Shanghai and estimates advertising expense to be five percent of the total wholesale revenues from Hainan Qi Zheng. According to Hainan Qi Zheng, the order value is expected to reach $5.0 million in the calendar year 2010.

"We are pleased to report that our recently introduced Gummy Bear products have gained significant recognition and popularity among Chinese children. We are aggressively expanding our geographic footprint by entering into distribution partnerships with leading distributors in our target markets," commented Ms. Qinghua Hu, CEO of Niusule Biotech Corp. "We are positive about our engagement with Hainan Qi Zheng as our Shanghai distributor and expect to leverage its well-established network to introduce our products in Shanghai. We are confident of Hainan Qi Zheng's ability to meet its retail outlet targets for 2009 and 2010. We continue to seek distribution partnerships with other leading distributors in our target markets."

Source:

Niusule Biotech Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Using a molecular testing technology for faster and comprehensive diagnosis of brain tumors